How much? Pfizer expects to reap at least $26B from Covid vaccine in 2021
Pfizer’s Covid-19 vaccine is likely to bring in about $26 billion in 2021 revenues, which is more than $10 billion more than the biopharma behemoth previously predicted, the company announced Tuesday morning.
The company said that figure is based on signed contracts as of mid-April that amount to 1.6 billion doses of the vaccine to be delivered this year. And the dramatic uptick in guidance is due to additional supply agreements that have been signed since the company’s previous guidance. More may be coming too.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.